The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult...

Area of Science:

• Endocrinology
• Pharmacology
• Bone Biology

Background:

• Glucocorticoids (GCs) are potent catabolic agents affecting skeletal muscle and bone.
• Growth hormone secretagogues (GHS) stimulate endogenous growth hormone release, potentially mitigating GC-induced catabolism.

Purpose of the Study:

• To investigate the efficacy of the GHS Ipamorelin in counteracting the catabolic effects of GCs on skeletal muscle and bone in vivo.
• To evaluate the impact of combined GHS and GC administration on muscle strength and bone formation rates.

Main Methods:

• An adult female rat model was used, with animals receiving subcutaneous injections of methylprednisolone (GC), Ipamorelin (GHS), or both for 3 months.
• Muscle strength was assessed by measuring the maximum tetanic tension of calf muscles using a materials testing machine.
• Periosteal bone formation rate was quantified to assess bone metabolic activity.

Main Results:

• Combined administration of Ipamorelin and methylprednisolone significantly increased maximum tetanic muscle tension compared to GC alone.
• Periosteal bone formation rate was four-fold higher in the group receiving both GC and GHS compared to the GC-only group.
• Ipamorelin effectively counteracted the detrimental effects of methylprednisolone on both muscle and bone parameters.

Conclusions:

• The GHS Ipamorelin demonstrates significant potential in mitigating GC-induced muscle atrophy and bone loss.
• Simultaneous administration of GHS may offer a therapeutic strategy to preserve muscle strength and bone health in patients undergoing GC treatment.
• Further research is warranted to explore the clinical applications of GHS in managing GC side effects.